had advanced and bulky disease at the time of presentation. Using different drug combinations in a sequential manner as described below, results are as follows: of the initial 33 male patients, 22 (67 O ) have discontinued treatment (mean 9-5 months). Nineteen have responded completely and 3 have static computed tomography (CT) nodules. Life-table analysis projects a survival of 66% (analysis at 1 December 1979).
Nine out of 10 ovarian teratoma patients are alive. Adverse prognostic factors at the start of treatment were recognized in 9/10 male patients and the 1 female patient who have died. Although the survival of patients with malignant teratomas has improved dramatically, there are still problems with drug resistance in patients with very advanced disease. Patients with these tumours should continue to be treated in centres specializing in managing what has now become a potentially curable disease in most cases.
IT HAS LONG been recognized that metastatic malignant teratomas can respond dramatically at first to single-agent and combination chemotherapy. In 1960 Li et al. reported (Einhorn & Williams, 1979) shows that 28 (Peckham et al., 1979) . Most malignant teratomas produce hCG or AFP or both (Lange et al., 1976; Newlands et al., 1976; Scardino et al., 1977) . When these markers are at raised levels they provide the most rapid and (Newlands. 1978 : Higby et al., 1974 Hayes et al., 1977; Newlands & Bagshawe, 1977; Ne-wlands, 1976b) Partial responses with >50 % reduction in measurable lesions were divided into: (1) partial response with unresectable differentiated teratoma and negative tumour markers, referred to as PRD, (2) partial response with static residual nodules on CT scanning and negative tumour markers, referred to as PRCT, and (3) partial response with evidence of disease activity, referred to as PRA. No further maintenance therapy was given once a complete response, PRD or PRCT had lasted for 3 to 4 months.
Radioiimmunoassay
HCG and AFP were measured by a specific radioimmunoassay according to methods previously described .
RESULTS
The results in 33 male patients (excluding the 10 patients who are responding and still on treatment) show that 22 (67%) of the initial 33 patients have been off treatment for periods of 1-20 months (mean 9.5). There have been 19 (570) complete responses; 1 (3%O) PRD; 2 (6%) PRCT. Only 1 (3%) patient has drugresistant disease and PRA. So far only 1 patient who had a complete response has relapsed and is responding to treatment. Fig. 1 Table I . There has been 1 (70o) death in 13 patients with non-bulky disease. Nine (30%) of 30 patients with bulky disease have died. There were 6 deaths from resistant malignant teratoma after an initial response. The primary histology in these patients was: MTU, 5; MTT, 1. The other causes of death were: initial extent of disease, 1; massive pulmonary embolus in a patient responding to treatment, 1; septicaemia due to neutropenia, 1; pulmonary oedema while off treatment, 1. The patient who died from septicaemia had massive abdominal The tumour markers hCG and AFP are not only useful in monitoring therapy, they also have prognostic value for the outcome of therapy. Analysis of our previous series of male teratomas shows that when the hCG > 105 miu/ml and the AFP > 103 MRC u/ml there was a very poor prognosis (Germa-Lluch, Begent, Bagshawe, unpublished observations). The trend in the current group of male patients supports the use of these markers in identifying high-risk patients (Table II) .
A number of patients had residual CTscan abnormalities at the end of treat- The toxicity encountered with this chemotherapy is relatively mild, and less than our previous experience with regimens including high-dose vinblastine. Haematological toxicity is summarized in Table III . Febrile episodes associated with neutropenia and given antibiotic cover occurred in 13 (24%) of 53 patients. All patients experienced some nausea and vomiting on high-dose cis-platinum. Some patients had evidence of high-frequency hearing loss on audiometry, but in none of these was the hearing loss severe enough to be socially noticeable. Renal impairment was mild and the elevations in blood (Einhorn & WVilliams, 1979; Peckhaml et al., 1977) . Although the follow-up of our series is relativel, short, we hope that the strict criteria for defining complete remission, together withi histological confirmatrion of' the natuire of any residtual no(ltiles or mnasses, will mean that we will see few relapses in this group. Writh the Irapi(l improvemenit in therapy, wN- The recognition of ad verse prognostic factors such as the initial bulk of tumour masses, disease in particular sites such as the central nervouis system, together with very high levels of hCG', and AFP (Table Il andl uinpublished observations) mneans that patients who are going to be diffictult to cuLre can be identified from the start of treatmenit. Resuilts from several centres (Samuels et al., 1975; Einhorni & Doniohue, 1977; Stoter et al., 1979; Peckham et al., 1979; Cheng et al., 1978;  Golbey et at., 1 979) and ourselves inidicate that, the complete remission rate is high in patients presenting with small tumour burdens. Howeveer, those with gross tuimour btulk at the timne of starting treatment are the main soUrIce of therapeutic failture and in Einhorn's series (Einhorn & Donolhue, 1 977; Einhorn & WNTilliams, 1979) about 382 half the patients with bulky tumour have died. We do not regard the platinum, vinblastine, bleomycin regime (PVB) as standard therapy for this type of patient. In our view the main advantages of our sequential pattern of chemotherapy over PVB is that the major side effects are associated only with the courses of cisplatinum. The complications associated with high-dose vinblastine (marked neutropenia, myalgia, back-ache and constipation) are avoided.
Prior radiotherapy does not appear to be an adverse prognostic factor in this series, though the haematological toxicity with the chemotherapy was more pronounced (Table III) . In this group, the patients with prior irradiation were followed more closely, and presented with less advanced disease than the others. In patients with differentiated teratoma when the residual disease was resected, the aggressive parts of the tumour were closely associated with the trophoblastic and yolk-sac elements of the teratoma, producing hCG and AFP respectively. In the 2 patients (1 male, 1 female) with unresectable differentiated teratomas, the markers have been normal and the clinical situation has been static, which agrees with the favourable prognosis reported in this situation (Merrin et al., 1975; Hong et al., 1977) . Sixteen patients in this study have had surgery after bleomycin therapy, and so far there has been no pulmonary toxicity.
Malignant ovarian teratomas are rare, but in our small series many of the therapeutic lessons learnt from male malignant teratomas are clearly applicable. Nine of the 10 patients had raised tumour markers and these correlated closely with response to therapy and clinical remissions. Previous reports (Curry et al., 1978; Cangir et al., 1978; Slayton et al., 1978) treated our ovarian teratomas in the same way as the male teratomas. More of these patients had less advanced disease than the male patients, and this probably contributes to the good prognosis shown in Fig. 3 . We have also treated a limited number of other germ-cell tumours during this period: 6 male teratomas which had persisted after extensive previous chemotherapy at other centres (complete remission, 2; resistant active disease, 1; dead from malignant teratoma, 3). We have also treated 3 advanced seminomas (2 are in remission and 1 is dead) and 1 advanced dysgerminosa, who is in complete remission. The introduction of cis-platinum in drug combinations in the management of advanced malignant teratomas has produced a dramatic improvement in the proportion of patients achieving a complete remission, and many of these will probably be cured. With the number of chemiotherapeutic agents active against malignant teratomas, including VP. (Newlands, 1978; Newlands & Bagshawe, 1977; Fitzharris et al., 1980) we feel that further improvements can be made in therapy by finding the best combination of these agents. We think that the sequential chemotherapy results that we have reported here are as good as any other reported series, allowing for the high proportion (70%) of the male patients presenting with advanced and bulky disease.
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Note added in proof
Modification of treatment schedules since 1.12.79. Since this analysis we have modified the treatment sequences because several patients showed tumour resistance to treatment C and there has been no major toxicity from repeating treatment A more than twice. The current sequence of treatment is: A,A,B,A, B,D,B,D, etc.
